Cyxone revises strategy for commercial alignment targeting valuable market opportunities
Cyxone (publ), a biotech company in autoimmune diseases, with its lead asset rabeximod under development in rheumatoid arthritis, is revising its previous strategy due to important patent grants and valuable market opportunities.During 2023 a range of new biosimilar disease modifying anti-rheumatic drugs (DMARDs), approved by the US Food and Drug Administration, FDA, have been broadly introduced to the American market. As a result, patients with moderate to severe rheumatoid arthritis that have inadequate response to methotrexate will now be offered a range of less costly TNFa inhibitor